Study to Evaluate the Efficacy & Safety of Loncastuximab Tesirine Versus

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848765` - Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	Phase 2
Withdrawn	`NCT04635683` - Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Phase 1
Active, not recruiting	`NCT01955499` - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1
Not yet recruiting	`NCT06068881` - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	Phase 2
Active, not recruiting	`NCT03583424` - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04007029` - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 1
Withdrawn	`NCT03579927` - CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT04578600` - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Phase 1
Recruiting	`NCT04447716` - An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Phase 1
Recruiting	`NCT05025800` - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT03019640` - Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT02927964` - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	Phase 1/Phase 2
Completed	`NCT02869633` - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Phase 2
Active, not recruiting	`NCT02568553` - Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Phase 1
Completed	`NCT01995669` - Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	Phase 1/Phase 2
Withdrawn	`NCT05152459` - Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03401853` - Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	Phase 2
Active, not recruiting	`NCT03479268` - Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT06191887` - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT02956382` - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	Phase 1/Phase 2

NCT number	NCT04699461
Study type	Interventional
Source	ADC Therapeutics S.A.
Contact
Status	Terminated
Phase	Phase 2
Start date	November 4, 2021
Completion date	November 25, 2022

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma — LOTIS-6

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms